RxDoctor Payments Data

Pamela Telisky, DO

Cardiovascular Disease · Albany, NYNPI 1871973602

Payments from drug & device makers

$5,978in general payments, 2019–2025

Across 50 payments — averaging $119.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$685
  • Boston Scientific$660
  • AstraZeneca$249
  • Cvrx, Inc.$214
  • Bard Peripheral Vascular, Inc.$174
  • plus $883 from 12 others

What the payments were for

  • Grants$2,60043%
  • Food & beverage$2,83347%
  • Education$5469%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,978 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$307,784
Medicare patients
756
Services billed
8,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$65,814
BrilintaTicagrelor23$22,187
EntrestoSacubitril/Valsartan13$17,876
OzempicSemaglutide11$15,082
ClopidogrelClopidogrel Bisulfate103$1,413
Atorvastatin Calcium113$1,291
Ranolazine ErRanolazine25$1,110
Rosuvastatin Calcium85$947
Nifedipine ErNifedipine48$889
Metoprolol Succinate68$676
Verapamil SrVerapamil Hcl12$570
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$557
Olmesartan Medoxomil36$542
Amiodarone Hcl13$535
Losartan Potassium46$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$65,81461 claims
AstraZenecaBrilinta$249$22,18723 claims
NovartisEntresto$130$17,87613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →